VICTORVILLE — A new prostate cancer scan that is extending the lives of patients is now available in the High Desert. Axumin is a recently FDA-approved imaging agent that detects recurrent cancer ...
BURLINGTON, Mass. & OXFORD, England--(BUSINESS WIRE)--Blue Earth Diagnostics, a Bracco company focused on molecular imaging diagnostics, today announced results from an investigational clinical trial ...
In patients with PSA levels ≤ 1.78 ng/mL, 15 of 25 had a positive scan, with 11 confirmed as positive by histology; 71 of 74 patients with PSA levels > 1.78 ng/mL had a positive scan, of which 58 were ...
The U.S. Food and Drug Administration today approved Axumin, a radioactive diagnostic agent for injection. Axumin is indicated for positron emission tomography (PET) imaging in men with suspected ...
A phase 3 study from molecular imaging firm Blue Earth Diagnostics found that its Axumin contrast agent for PET scans could assist in the diagnosis of patients with glioma. Axumin, consisting of the ...
A new effective PET/CT scan for prostate cancer patients can detect the location and extent of cancer that has recurred after initial treatment. Prostate PET/CT scans can detect cancer earlier than ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback